Moomoo AIのまとめ
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated July 31, 2024, indicates significant shareholding activities by CBI USA, Inc. and DGP Co., Ltd. CBI USA, Inc., a Delaware-based entity, reported beneficial ownership of 818,299 shares, representing 9.5% of Exicure's class of common stock. DGP Co., Ltd., based in the Republic of Korea, reported beneficial ownership of 3,060,000 shares, representing 35.4% of the class. The filing includes an amendment to the stock purchase agreement between DGP and OverdigmK, extending the closing date for the balance of the DGP Sale to September 30, 2024. Additionally, an assignment and waiver agreement was entered into, allowing for the termination or assignment of the DGP Sale Agreement to a third party at DGP's request. These documents were filed as part of Amendment No. 13 to the Schedule 13D, which amends and supplements the initial filing and subsequent amendments dating back to June 1, 2022.
バイオテクノロジー企業であり、NASDAQの取引所歩み値XCURで取引されているExicure, Inc.は、米国証券取引委員会（SEC）にSchedule 13D/Aの提出対象となりました。2024年7月31日付の申請によれば、CBI USA, Inc.とDGP Co., Ltd.によって重大なシェアホールディング活動が行われています。CBI USA, Inc.はデラウェア州に本拠を置く企業で、Exicureの普通株式クラスの9.5%を占める818,299株の有益所有権を報告しました。また、大韓民国に拠点を置くDGP Co., Ltd.は、クラスの35.4%を占める3,060,000株の有益...すべて展開
バイオテクノロジー企業であり、NASDAQの取引所歩み値XCURで取引されているExicure, Inc.は、米国証券取引委員会（SEC）にSchedule 13D/Aの提出対象となりました。2024年7月31日付の申請によれば、CBI USA, Inc.とDGP Co., Ltd.によって重大なシェアホールディング活動が行われています。CBI USA, Inc.はデラウェア州に本拠を置く企業で、Exicureの普通株式クラスの9.5%を占める818,299株の有益所有権を報告しました。また、大韓民国に拠点を置くDGP Co., Ltd.は、クラスの35.4%を占める3,060,000株の有益所有権を報告しました。この申請には、DGPとOverdigmkの間の株式購入契約の修正が含まれており、DGP Saleの残りの部分の締め切り日が2024年9月30日まで延期されました。さらに、DGPの要請により、同意と放棄の契約が結ばれ、DGP Sale契約の終了または第三者への譲渡が許可されます。これらの書類は、初回申請および2022年6月1日以降の修正を修正および補完するAmendment No. 13の一部として提出されました。
役に立った
役に立たない